GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®
30 May 2012 | By GlaxoSmithKline
GlaxoSmithKline has submitted regulatory applications in the European Union and US...
List view / Grid view
News
Lilly’s commitment to global innovation reinforced with opening of new diabetes-focused research and development center in Shanghai
30 May 2012 | By Eli Lilly and Company
Eli Lilly & Company opened the LCRDC...
Biogen Idec continues support for MS community with worldwide celebrations on Fourth Annual World MS Day
30 May 2012 | By Biogen Idec
Biogen Idec will join with the MS community around the world...
Boehringer Ingelheim further strengthens animal health presence in China
30 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Taizhou China Medical City announced the signing of an agreement...
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents
29 May 2012 | By GlaxoSmithKline
GSK which has the marketing rights for Lovaza in the US and Puerto Rico...
GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma
29 May 2012 | By GlaxoSmithKline
GlaxoSmithKline plc. announced the start of a Phase III programme...
Lundbeck’s Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer’s disease
29 May 2012 | By H. Lundbeck A/S
The pivotal clinical programme is in planning...
Abbott to present wide range of investigational efficacy, safety and health outcomes data on HUMIRA®
29 May 2012 | By Abbott
Latest investigational research findings on HUMIRA®...
Sanofi inaugurates Lantus® SoloSTAR® pen assembly plant in its Beijing facility
28 May 2012 | By Sanofi
The group pledges continuous commitment to diabetes management in China...
Pfizer’s Axitinib receives positive opinion from the CHMP
25 May 2012 | By Pfizer
The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)...
Novo Nordisk receives positive opinion on recombinant factor XIII from the European regulatory authorities
25 May 2012 | By Novo Nordisk
Novo Nordisk receives a positive opinion on recombinant factor XIII product (rFXIII)...
Government of Rwanda introduces Merck’s ROTATEQ® to help protect children against rotavirus
25 May 2012 | By Merck
Merck welcomes the launch of Africa’s first national rotavirus vaccination program...
GSK receives positive opinion from European CHMP for pazopanib
25 May 2012 | By GlaxoSmithKline
Positive opinion recommending marketing authorisation for Votrient®...
Jentadueto™ tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe
25 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company has received a positive opinion from the EMA...
New Phase 3 data for Tradjenta® (linagliptin) tablets
24 May 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African…
